Year: 2014

Incanthera plc – Corporate Update & Board Changes

Jun 4, 2026

ImmuPharma plc (LSE AIM: IMM), the specialist drug discovery and development company, notes today’s announcement by Incanthera plc, “Incanthera”, regarding a corporate update and subsequent Board changes. As part of the Board changes, Tim McCarthy has stepped down as Executive Chairman of Incanthera: Link: https://incanthera.com/ news-media/. To download form Click here
Notice of AGM & Annual Report & Accounts

Jun 2, 2026

ImmuPharma PLC (LSE AIM: IMM), the specialist drug discovery and development company, confirms that the Notice of Annual General Meeting (“AGM”) has today been posted to shareholders. The Annual Report and Accounts for the year ended 31 December 2025 has also been posted to shareholders today. These documents will be available shortly, in electronic form,…
FINAL RESULTS for the twelve months ended 31 December 2025

May 27, 2026

ImmuPharma PLC (LSE:IMM), (“ImmuPharma” or the “Company”), the specialist drug discovery and development company, is pleased to announce its Final Results for the twelve months ended 31 December 2025 (the “Period”). Key Highlights (including post Period review) Financials Portfolio P140 technology platform Kapiglucagon Partnering opportunities Management and Board updates Commenting on the statement and outlook…
ImmuPharma Initiates IND-Enabling Program for Kapiglucagon to treat Diabetes

May 5, 2026

ImmuPharma plc, (LSE AIM: IMM), the specialist drug discovery and development company, is pleased to announce the initiation of IND-enabling activities for its Kapiglucagon diabetes program, following the execution of a ‘Work Order’ with specialist pharmaceutical consultancy tranScrip Limited (“tranScrip”). Under the agreement, tranScrip will support the development of the regulatory strategy and the preparation…
TR-1: Standard form for notification of major holdings

Apr 10, 2026

TR-1: Standard form for notification of major holdings from Lanstead Capital Investors LP To download form Click here
Chairman’s Open Letter to Shareholders

Apr 9, 2026

ImmuPharma PLC (LSE:IMM), the specialist drug discovery and development company, outlines below an open letter to shareholders from the Chairman, Tim McCarthy. This follows on from this week’s announcement, confirming that both resolutions proposed at the General meeting held on Tuesday 7 April 2026, were approved by Shareholders. Dear Shareholders I wanted to take this…
Result of General Meeting and TVR – Resolutions Approved

Apr 7, 2026

ImmuPharma PLC (LSE:IMM), the specialist drug discovery and development company, is pleased to announce that both resolutions proposed at the General meeting held earlier today were approved by Shareholders. This is further to its Fundraising announcement published on 17 March 2026 at 7:00 a.m. (the “Fundraising RNS“) and the WRAP Retail Offer announcement published on 17…
P140 Program Update patent progress |new supporting data | scientific publication in preparation

Mar 27, 2026

ImmuPharma PLC (LSE AIM: IMM), the specialist drug discovery and development company, is pleased to provide an update on its auto-immune technology platform program, P140. The Company has received a first Combined Search and Examination Report (“CSER”) in relation to its United Kingdom patent application for P140, filed in September 2025. The supportive response is…
Result of WRAP Retail Offer and TVR

Mar 23, 2026

ImmuPharma PLC (LSE:IMM), the specialist drug discovery and development company, further to its Fundraising announcement published on 17 March 2026 at 7:00 a.m. (the “Fundraising RNS“) and the WRAP Retail Offer announcement published on 17 March 2026 at 7:01 a.m. (the “WRAP RNS“), announces the result of the WRAP Retail Offer and provide an update on…
IMC presentation

Mar 20, 2026

IMMUPHARMA PLC – Corporate Update 20 March 2026 ImmuPharma PLC (IMM@AIM) provided an investor update outlining its strategic funding decision, pipeline progress, and growth strategy, reaffirming that its lead asset P140 remains the core value driver with ongoing licensing discussions and strong scientific validation supporting potential deals in 2026. The company highlighted continued progress on…

Lisa Baderoon

Non-Executive Director and Head of Investor Relations

Lisa has spent over 25 years working within the City of London being involved with a diverse portfolio of clients from a variety of sectors but with a leaning towards emerging, high growth businesses advising both private and public companies on their financial and corporate strategies aligned to stakeholder and investor interests, as well as a strong acumen in media communication. During this time, she has been involved in a multitude of client transactions spanning private fund raisings, Initial Public Offerings (IPOs), secondary high profile capital raisings and mergers and acquisitions both in the UK and internationally.

Lisa had a successful career spanning 20 years as a Partner at Buchanan Communications, one of the leading City financial public relations agencies. As one of the youngest Board members, she was involved in the successful five-year earnout, as part of Buchanan being acquired by the FTSE 100 rated WPP Plc in 1997.

Lisa founded Just B Communications Ltd in 2012 with the key objective of working with a more select number of clients and providing a greater degree of bespoke advisory services thus becoming more integral to the day to day corporate and strategic development for these businesses. She has successfully advised a number of public and private companies, at Board level, on corporate strategy, stakeholder and investor communications, capital raisings, dual listings, licensing and M&A. Media profiling, where required, has also played an important role in advisory activities.

Lisa was appointed Head of Investor Relations at ImmuPharma in 2012 and most recently appointed as a Non-Executive Director in July 2021.

Ketan Patel

Independent Non-Executive Director

Ketan is an experienced investment professional who brings extensive expertise in financial markets, with a particular focus on the UK healthcare and life science sectors. He has been a long-term investor in UK markets, working as both an analyst and Fund Manager, managing institutional, retail, and charity mandates. Ketan began his career at JP Morgan before moving to Insight Investment, where he served as a global Pharmaceutical and Healthcare analyst. He then spent over 20 years at EdenTree Investment Management, where he was responsible for UK equity and global equity income strategies, consistently delivering upper-quartile performance.

Ketan combines rigorous fundamental analysis with risk-focused investment strategies. He is also a published thought leader on sustainability and investment themes. Ketan is a CFA Charterholder and holds an MSc in Economic History from the London School of Economics, an MSc in Geography from King’s College London, and a BA (Hons) in History and Geography from Queen Mary University, London.

Dr Laurence Reilly MD, LLM

Senior Independent Non-Executive Director

Dr Laurence Reilly has been appointed as Senior independent Non-Executive Director and Chair of the Audit Committee. Dr Reilly brings extensive experience in managing late-stage clinical programs through to approval, in addition to commercial and business development experience.

He is currently Vice President of Research & Investments, working with Royalty Pharma, a New York based life science investment company focussing on acquisition of biopharmaceutical royalties and funding of innovation across the biopharmaceutical industry.

Through his consulting practice (Acumen Life Science Investment Consulting) Dr Reilly has provided strategic consulting and due-diligence services to biotech companies, life science venture capital and private equity clients. He also served as Chief Medical Officer for Cellectar Biosciences, New Jersey, a late-stage oncology biotech company. Prior to founding his consulting practice, Dr Reilly served as Chief Scientific Officer and Vice President at Avillion, a drug development company focused on the co-development and financing of drug candidates, where he was responsible for clinical and strategic oversight of co-development programs and partnering with both large pharma and biotech, including Pfizer, Merck KGaA and AstraZeneca. Dr. Reilly previously served as a Clinician – Clinical Development & Medical Oversight at Pfizer and at Lundbeck as Medical & Scientific Advisor.

Dr Reilly earned his medical degree from the University of Liverpool Medical School, U.K., and practiced as Neurosurgery Resident at Queen Elizabeth University Hospital in Birmingham. Dr Reilly also holds a Masters Degree in Law from De Montfort University, U.K.

Ashley Clarke ACA

Chief Financial Officer & Company Secretary

Ashley brings over a decade of experience in the financial sector. She began her career at a Big Four accounting firm and later advanced her professional expertise by earning her ACA qualification with a respected local firm.

Her professional journey is rooted in auditing, where she developed expertise working with a diverse portfolio of audit and non-audit clients across various industries. Ashley’s experience spans from supporting SMEs to managing large international group consolidations, giving her a comprehensive understanding of financial management across different business scales.

Ashley has been closely involved with the company’s accounts for several years via outsourced accountants, providing her with deep familiarity with its operations. Now, as Group CFO and Company Secretary, she is poised to leverage her extensive knowledge to drive strategic financial growth and ensure robust fiscal management.

Dr Sébastien R. Goudreau Ph.D.

Chief Scientific Officer

Born in Sherbrooke, Québec, Canada, Dr. Sébastien Goudreau obtained his PhD in Chemistry from the Université de Montréal as an NSERC fellow before conducting postdoctoral research at ETH Zürich as an FRQNT fellow. He later returned to Canada, where he co-founded FindMolecule Inc. and worked in the pharmaceutical industry.

Dr. Goudreau joined ImmuPharma in 2014 as Research Director and established the Ureka research laboratories in Bordeaux. Following the merger of ELRO and Ureka in 2019, he became Chief Scientific Officer of Ureka Pharma. In 2021, he was appointed Chief Executive Officer of ImmuPharma Biotech, and since 2025 he has served as Chief Scientific Officer of the ImmuPharma Group.

Dr. Goudreau and his team are credited with the discovery and development of several innovative programs, including BioAMB, BioCIN, the P140 companion diagnostic, and Kapiglucagon.